Company: SXTPW
Filing Date: 2025-07-16
Form Type: 424B4
Source: 0001213900-25-064472
Chunk: 49

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-07-16
Form: 424B4
Chunk 49
---
 our business segments; |

| ● | Our ability to manage our research,                    
 development, expansion, growth and operating expenses; |

| ● | Our ability to evaluate and                              
 measure our business, prospects and performance metrics; |

| ● | Our ability to compete, directly                                           
 and indirectly, and succeed in a highly competitive and evolving industry; |

| ● | Our ability to respond and                            
 adapt to changes in technology and customer behavior; |

| ● | Our ability to protect our                                                     
 intellectual property and to develop, maintain and enhance a strong brand; and |

| ● | Other factors (including the                                                                                      
 risks contained in the section of this prospectus titled “Risk Factors”) relating to our industry, our operations 
 and results of operations.                                                                                        |

Should one or more of these risks or uncertainties
materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed,
estimated, expected, intended or planned.

Factors or events that could cause our actual
results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results,
levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States,
we do not intend to update any of the forward-looking statements to conform these statements to actual results.

<div align='center'>USE OF PROCEEDS</div>

We estimate that we will receive net proceeds from this offering of
approximately $4,181,431, based on a public offering price of $1.90 per share and accompanying warrants and assuming the exercise of all
the Pre-Funded Warrants sold in this offering, after deducting the estimated placement agent fees and estimated offering expenses payable
by us and assuming no exercise of the Warrants being issued in this offering. However, because this is a best-efforts offering and there
is no minimum offering amount required as a condition to the closing of this offering, the actual offering amount, the placement agent’s
fees and net proceeds to us are not presently determinable and may be substantially less than the maximum amounts set forth on the cover
page of this prospectus.

We currently intend to use the net proceeds from
this offering for working capital and general corporate purposes.

We will retain broad discretion in the allocation
of the net proceeds from this offering and could utilize the proceeds in ways that do not necessarily improve our results of operations
or enhance the value of our common stock.

Pending application of the net